It has been suggested that epidermal Langerhans cells (LC) bearing immunoglobulin E (IgE) may be involved in the genesis of atopic disease. The identity of the IgE receptor(s) on LC remained unclear, although it represents a crucial point in understanding cellular events linked to the binding of allergens to LC via IgE. In this report, we demonstrate that epidermal LC express the high affinity receptor for the Fc fragment of IgE (FceRI) which has, so far, only been described on mast cells and basophils. Epidermal LC react with antibodies specific for the u subunit of the tetrameric (oL,~,23') FceRI. Specific transcripts for Fc~RIo~ and FceRI3~ were detected in LC and correspond to those of human basophils and of the human basophil cell line KU812. Furthermore, human basophils, KU812 cells, and LC express the putative B subunit. Thus human LC express the complete structure of FceRI. This finding opens new perspectives in the putative functional role of this structure on antigen-presenting cells.
T
he demonstration of IgE molecules on epidermal Langerhans cells (LC) 1 in patients with atopic dermatitis has implied that these cells should perform a major function in the pathophysiology of atopic disease (1, 2) . Although initially, only receptors for the Fc fragment of IgG were identified on epidermal LC (3, 4) , the low affinity receptor for IgE FceRII/CD23 (5) and the human IgE binding protein (eBP) (6) have now also been found on these cells in lesional, as well as in normal skin. However, attempts to completely block IgE binding on LC by a variety of anti-FceRII/CD23, antieBP, and/or anti-Fc3,R reagents remained unsuccessful, suggesting the presence of a third IgE-binding structure actually responsible for a part of the IgE-binding capacity of LC. We report here, that normal human LC also express the high a~nity receptor for IgE, Fcelkl, demonstrating that the presence of this structure is not restricted to mast cells and basophils. Our results also document the presence of the putative/~ chain on both human basophils and LC.
1 Abbreviations used in this paper: BP, binding protein; ECL, enhanced chemiluminescence; LC, Langerhans cells.
Materials and Methods
Individuals and Biopsy Specimens. Fresh human skin specimens were obtained during plastic abdominal surgery or reduction mammoplasty. 6-mm punch biopsies were taken from the buttocks of healthy volunteers. All samples were immediately processed.
Basophils and Basophilic Cell Line.
Human basophils were obtained by standard isolation technique from the peripheral blood of healthy volunteers (7) . The human basophilic KU812 cell line was a kind gift from Dr. Becket (Forschungsinstitut, Borstel, Germany). These cells, which constitutively express FceRI (8), were cultured in RPMI 1640 (Gibco, Berlin, Germany) supplemented with 5% FCS (Gibco), antibiotics, and antimycotics (Gibco).
Reagents. Unlabeled mAb IOT6 (IgG1; Immunotech, MarseiUe, France), and PE-labeled T6/RD1 (IgG1, Coulter Corp., Krefeld, Germany) react with CDla which is, in the skin, exclusively expressed on LC (9) . Murine mAb 29C6 and 6F7 (both IgG1) were raised from mice immunized with a purified chimeric c~ subunit ofFceRI (FceRIo 0 expressed in Chinese hamster ovarian cells (10 In Situ Immunolabeling on Cryosections. 6-#m cryosections were prepared from the punch biopsies, air-dried, fixed for 10 min in pure acetone, and then processed for immunohistochemistry using the mAb IOT6a, 29C6, 6F7, or the IgG1 isotype control (all at 10 gg/ml) and the alkaline-phosphatase mouse anti-alkalinephosphatase technique as described previously in detail (2) .
Preparation of Epidermal Cell Suspensions and Enrichment of LC.
Isolation and enrichment of LC from fresh human skin specimens was performed as described in detail elsewhere (5 lmmunomagnetic Depletion~Purification of CDIa § Cells. The separation of CDla + LC for the preparation of LC-depleted epidermal cells (EC), or for purification of LC was achieved according to the manufacturer's protocol. The purity of the LC preparation was controlled after each application on the magnet by light microscopy, and the procedure was stopped when unbound cells, i.e., keratinocytes and other cells, were completely removed. Addition of the beads and depletion procedure were repeated three to four times. The LC depletion of EC was controlled by anti-CDla staining and flow cytometric analysis.
Imrnunobiochemical Analysis of FceRI on Epidermal Cells. Puri-
fied LC or LC-depleted EC were prepared by positive selection as described above. The cells were washed, lysed in NP-40 (Sigma Chemical Co.)-containing buffer and 14 #g of protein were separated by 12% SDS-PAGE. Then, separated proteins from purified LC or from LC-depleted EC were electroblotted onto nitrocellulose (Hybond C; Amersham Corp., Arlington Heights, IL). The strips were blocked with dry milk, and incubated for 1 h with either the anti-FceRI~ 29C6 or the isotype control (both at 10 /~g/ml). Binding of the primary antibody was revealed by incubation with a peroxidase-conjugated goat anti-mouse Ig antibody followed by an enhanced chemiluminescence (ECL) Western blot detection system, according to the manufacturer's protocol (Amersham Corp.).
Amplification of mRNA Transc@ts. Total KNA was isolated from purified LC, 1.C-depleted EC, basophils, and KU812 cells by standard procedure (11) , and eDNA was synthesized by extension of 3 pmol of reverse primers specific for tryptase, FceRIo~, or FceRI3, on 100 ng of total RNA by Moloney routine leukemia virus (MoMLV) reverse transcriptase (Gibco). The second-strand synthesis and 30 cycles of amplification were performed directly after the reverse transcription step by adding 10 pmol of direct primers, 10 pmol of the reverse primers, 1.25 mM of each dNTP, and 1 U of Taq DNA Polymerase (Perkin-Elmer Cetus Corp., Norwalk, CT). For FceRIfl, eDNA was synthesized by extension of 10 pmol of reverse primer on 100 ng of total LC-RNA, or 1/~g of total RNA from basophils. The second-strand synthesis and 35 cycles of amplification were performed by adding 20 pmol of direct primer and 50 pmol of the reverse primer, 1.25 mM of each dNTP, and 1 U ofTaq polymerase. Temperatures were 94~ for denaturation, 55~ for annealing of FceRIc~ and FceRI% 58~ for annealing of FceRIB, and 72~ for polymerizations. Sequences of PCR primers were as follows: for tryptase based on (12) 
Results and Discussion
Immunodetection of FceRI on Epidermal LC. Fc6RI is a tetrameric structure composed of one 50-55-kD ol chain (FceKIot), one 33-kD fl chain (FceRIfl), and two disulphide-linked identical 7-9-kD 3' chains (FceRI'y) (16) . Recently, a series of anti-FceKIoe mAbs were raised from mice immunized with a purified chimeric FceRIol expressed in Chinese hamster ovarian cells (10) . Using two of these reagents, the anti-FceRIot antibodies 6F7 and 29C6, we investigated the expression of Fc.eRIo~ on cryosections from normal human skin by immunohistochemistry. Positive staining was found not only on dermal mast cells but also on some dermal dendritic cells and, most important, on dendritic cells in a suprabasal localization in the epidermis (Fig. 1 A) where mast cells have never been observed. Preliminary experiments on cryosections revealed that, as expected from the characterization of these antibodies (10), 6F7 blocks the IgE binding on epidermal dendritic cells, as well as on dermal mast cells, while 29C6 is ineffective. To ascertain that FceP,.I-reactive epidermal dendritic cells were LC, double-labeling experiments and flow cytometric analysis were performed on freshly isolated LC-enriched EC using anti-FceRIoc and anti-CDla reagents. As expected, antiFceKIo~ antibodies only reacted with CDla-expressing EC, i.e., with LC ( Fig. 1 B, panels b and c) , thus excluding a contamination of isolated EC with other FceRIol-expressing cells, e.g., mast cells.
Biochemical characterization of the anti-FcdLIce reactive structure by immunoblot analysis on lysates from purified LC revealed a structure of an apparent molecular mass of 50 kD (Fig. 2, lane 1) , which is consistent with the oe subunit of FcetLI (16) . The fact that lysates from LC-depleted EC failed to react with anti-FceRIc~ antibodies (Fig. 2, lane 2 ) strongly indicates that, in the epidermal compartment, FceRIcr expression is restricted to LC.
Identification of the FceRI ol and y Subunits mRNA in LC. A molecular genetic approach based on KT-PCR with specific primers for human FceKIoe and FCeKI3, was chosen to further characterize the structure of FceRI on human LC. Agarose gel electrophoresis analysis of the amplification products obtained from purified LC using the primers for FceKI subunits revealed the predicted 495-and 364-bp fragments for FceKIcx and FceKI% respectively (Fig. 3 b, lanes I and 3) . These fragments correlated exactly with the results obtained with peripheral blood basophils (Fig. 3 b, lanes 5 and 7) and KU812 cells (not shown) which were used as a positive control. The specificity of the fragments was confirmed by restriction enzyme analysis of the KT-PCI~ products of purified LC and basophils (with HindlI, PvulI, and Sail for the 3, chain, and with StuI, PvulI for the cx chain, data not shown), and by Southern analysis with oligonucleotidic probes specific for Fc~RIc~ (Fig. 3 c, lanes 1 and 5) and FceKI'y (Fig. 3 c, lanes  3 and 7) . KT-PCtL experiments using the primers for Fc~KIc~ and FceRI7 on KNA from LC-depleted EC remained negative, while weakly positive in crude EC KNA (data not shown). It should be mentioned that the possibility of a contamination by dermal mast cells or basophils was formally excluded in either condition, since KT-PCIL experiments using 4; 6 and c, lanes I-3), from human basophils (a, lane I; b and c, lanes 5-7) , and the cell Line KU812 (a, lane 3) . digested pBR322 (1,444, 1,305, 475, 368, 315, 313, and 141- TTT TCA TCA   III II  II  II III II II II  I  II  I  II I I  209  A~A TGC CTT TGT TTT GGA A~ ATT GTC T~  GTA CTC TAT GTT TCA GAC TTT H~ 76  TTT ~  GCA  T TAT CCA TTC T~ G~ GCC ATA TTT TTT TCT ATT TCT GGA ATG TTG TCA ATT ATA  G~ A~  I I Ill  I  III III III III II  II  I  I III  I I XII III  I III III I~I II  III II  284  TAT ~  CTA ~C TAT C~ T~ T~ GGT GCA GTG CTG TTT GTT TTG TCT G~ TTT TTG  ATC TCC G~ the primers for the tryptase remained negative on purified LC RNA (Fig. 3 a, lane 4) , while a fragment of ~620 bp was easily amplified from peripheral blood basophils RNA and from the control cell line KU812 ILNA (Fig. 3 a, (18) and that, in humans, the cotransfection of FceRI3' appears necessary and sufficient for the expression of FceRIc~ at the cell surface (19) . Thus the question remained whether human basophils and LC express a putative B chain. Since cloning and sequencing of the human FceRI/ 3 have not yet been published, tLT-PCIL of the human Fc~R/~ was attempted using oligonucleotides designed on the basis of two observations: (a) the murine FceILI~ and Ly 44, the routine equivalent of CD20, are structurally homologous and include four transmembrane domains; (b) the amino acid sequences of the murine Ly 44 and the human CD20 are quite well conserved, especially within their transmembrane domains (20) . Moreover, given that cysteines should be very probably conserved in the transmembrane domains, one primer corresponding to nucleotide numbers 209-238 of the mouse FceRIB cDNA (14) was synthesized, whereas the other primer was deduced from the COOH-terminal intracytoplasmic domain. To increase the probability of success of the tLT-PCR, two inosines and one codon degeneracy were introduced in the first and second primers, respectively. We thereby isolated a 457-bp product from total RNA of peripheral basophils (Fig. 3 b, lane 6 ). Cloning and sequencing of this fragment revealed 71% homology to the corresponding fragment of the FceRIB in the mouse (Fig. 4) . This fragment encodes a polypeptide that presents 54% identity with a portion of the mouse FceRI~, the most homologous region (68% identity) being the transmembrane domains. By screening EMBL and SWISS-PILOT databanks using the PCGene program, significant homologies were found only with the mouse and rat FcEILI~. Moreover, the same fragment could be amplified by RT-PCIL from KU812 RNA (data not shown). Given these data, we assume that we have isolated a cDNA fragment of the human B chain. Using these primers, we then amplified transcripts from total RNA of purified LC and obtained the expected fragment of 457 bp (Fig. 3 b, lane  2) . The identity of this fragment was confirmed by Southern analysis (Fig. 3 c, lane 2) using an oligonucleotide deduced from the sequence of the above described cDNA cloned from the basophils (Fig. 3 c, lane 6) .
Taken together, our results clearly demonstrate that resident or freshly isolated human LC express the three components of FceRI. To our knowledge, this is the first report on the expression of FceRI on cells distinct from mast cells and basophils. It remains to be determined whether, as for mast cells or bone marrow-derived precursors of basophils (21) , cross-linking of IgE via FceP, I on LC may activate the cells or induce the secretion of cytokines, which in turn possibly initiate a series of events leading to inflammatory reactions in the skin or other tissues where these cells are localized. 
